PUBLIC COMPANY
save$AXSMAxsome Therapeutics, Inc.
$AXSM179.25-1.55%New York, NY, USupdated 1d ago
community read0 votes
pipeline
5
marketed
3
phase 3
1
catalysts ytd
5
approvals ytd
0
recalls ytd
0
Pipeline(5)
pipeline depth5 products
1Phase 33Marketed1Unknown
Marketed
(bupropion hydrochloride + dextromethorphan) ER
Dementia Associated With Alzheimer's Disease
Marketed(meloxicam + rizatriptan benzoate)
Migraine
Marketedsolriamfetol hydrochloride
Obstructive Sleep Apnea
Phase 3reboxetine
Type 1 Narcolepsy (Narcolepsy with Cataplexy)
drugAUVELITY
1 INDICATIONS AND USAGE AUVELITY is indicated for the tre…
Sodium-dependent dopamine transporterSodium-dependent noradrenaline transporter
Upcoming
Recent(90d)
earnings (2)
Active trials
- phase3Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
- phase3An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
- phase3A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
- phase3Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
- phase2Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)
- phase3Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- phase3An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
- phase3A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 22, 26SELLMaizel Ari· Chief Commercial Officer−$1.37M↗
routine RSU / option mechanics (6)
- Apr 22, 26option exerciseMaizel Ari · Chief Commercial Officer7,500 sh
- Apr 22, 26option exerciseMaizel Ari · Chief Commercial Officer7,500 sh
- Apr 21, 26grantMaizel Ari · Chief Commercial Officer7,224 sh
- Apr 21, 26grantPizzie Nick · Chief Financial Officer8,188 sh
- Apr 21, 26grantMurdock Hunter R. · General Counsel7,224 sh
- Apr 21, 26grantJacobson Mark L. · Chief Operating Officer8,669 sh
🐶 Hiring Signal
next earnings Nov 2, 2026
News
- Summit’s ‘self-inflicted’ stumble; Esperion’s take-private dealSummit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast c…biopharma_dive · 5mo ago
Data sources
last refreshed 45m ago
Found something off?
comments(0)
5-min edit window · permanent after that